CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Mark Eisner

Executive Vice President & Chief Medical Officer, VIR BIOTECHNOLOGY INC

Search every verified Mark Eisner interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a September 2020 interview, Mark M.p.h., Executive Vice President & Chief Medical Officer at Vir Biotechnology, discussed the company's focus on infectious diseases. He stated that "the pharma industry has reduced its emphasis on infectious diseases; there's a huge need for better drugs and that's why Vir exists." He noted that the company is concentrating on hepatitis B, flu, HIV, and tuberculosis, adding that "many of the patients are not yet diagnosed." M.p.h. also commented on the business dynamics of developing cures for viral diseases. He referenced Gilead's experience with hepatitis C, saying it was "dramatically rewarded by the market and then dramatically punished when they couldn't come up with the next cure." He expressed a view that a potential cure for hepatitis B would differ, stating, "I think hepatitis B will be different from hepatitis C... I don't think it's going to be a hepatitis C kinetics where you have a huge market and you cure everybody in a couple years and then the market falls off; it would be much more slowly."

Recent appearances

  • Executing A Product Pivot With Vir's Mark Eisner, MD

    May 11, 2025 · 📺 Life Science Connect

    On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Biotechnology, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how he reprioritized the company's development candidates and assimilated Sanofi's acquired T cell engager platform, and his own transition from healthcare provider to clinical research. This episode is brought to you by Avantor. For more information, visit avantorsciences.com Subscribe to the podcast on your preferred platform or watch the vide…

    Watch on YouTube ↗

  • Vir Biotechnology CEO on treating hepatitis

    January 14, 2020 · 📺 CNBC Television

    Vir Biotechnology CEO George Scangos talks with CNBC's Meg Tirrell to break down the company's outlook. For access to live ...

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →